SV2 PET Imaging With [11C]APP311
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT03995121
- Status
- Recruiting
Conditions
- Cannabis Use Disorder
- Healthy
- Schizophrenia and Other Psychotic Disorders
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Accepted
Interventions
- [11C]APP311 — DRUGIt has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
Study Details
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Key Dates
- Start date
- Dec 1, 2017
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 250 participants (estimated)
Arms
- Arm: Schizophrenia and other psychotic disordersFor each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
- Arm: Cannabis Use DisorderFor each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
- Arm: Healthy ControlFor each \[11C\]APP311 PET scan, up to 20 mCi of \[11C\]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
Primary Outcome Measure
Synaptic density in psychiatric disorders using SV2A receptor PET Imaging with [11C]APP311 [ Time Frame: One test day (one time point). ]
Central Contacts
- Angerlyk Frytz, MD203-974-7822
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Conneticut Mental Health Center | New Haven | Connecticut | 06519 |
Find similar trials in New Haven, CT
By research site
Related Studies
- SV2A Density Cannabis Use DisorderEARLY_PHASE1 · Recruiting · Yale University · New Haven, Connecticut
- SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral TherapyPHASE1/PHASE2 · Recruiting · Yale University · New Haven, Connecticut
- Genetics of Cannabis Use Disorder and Cannabinoid Response in HumansPHASE1 · Recruiting · Yale University · West Haven, Connecticut
- Integrated Treatment for Enhancing Growth in Recovery During AdolescenceRecruiting · Massachusetts General Hospital · Farmington, Connecticut